This document provides an analysis of the global hepatitis B virus treatment market from 2017 to 2022. It covers market segments by type (therapeutics and vaccine), end user (male and female), region (North America, Europe, Asia Pacific, and rest of world), and key countries. The report analyzes historical and forecast market size, growth drivers, restraints, competitive landscape, regulatory landscape, and company profiles of major players. It provides a comprehensive overview of market opportunities and forecasts for the global hepatitis B treatment market.

1. (c) AZOTH Analytics
Global Hepatitis B Virus [HBV] Treatment Market - Analysis By
Type (Therapeutics, Vaccine), By End User (Male, Female) - By
Region, By Country: Opportunities and Forecast (2017-2022)
• By Region- North America,
Europe, APAC and RoW
• By Country - United States,
Canada, United Kingdom,
Germany, France, China, India,
Japan
• Company Analysis
February 2018

2. (c) AZOTH Analytics 2
Product Coverage
Global Hepatitis B Virus [HBV] Treatment Market - Analysis By Type (Therapeutics, Vaccine), By End User
(Male, Female) - By Region, By Country: Opportunities and Forecast (2017-2022)
 Global Hepatitis B virus Treatment
Market Historical (2012-2016), By
Value
 Global Hepatitis B virus Treatment
Market Forecast (2017-2022), By
Value
 Global Hepatitis B virus Treatment
Market, By Type (2012-2022), By
Value
 Global Hepatitis B virus Treatment
Market, By End User (2012-2022),
By Value
 Hepatitis B virus
Treatment Market, By
Type (2012-2022), By
Value
 Hepatitis B virus
Treatment Market, By
End User (2012-2022),
By Value
Regional Coverage
 North America
 Europe
 Asia-Pacific
 ROW
 g
 Country Coverage
 Regional Coverage
 Scope of the Study By Type- Therapeutics and Vaccine
By End Users- Male and Female
Country Coverage
 USA
 Canada
 U.K.
 Germany
 France
 China
 Japan
 India
 Product Benchmarking
 Policy and Regulatory Landscape
 Financial Analysis
 Sales
 EBITDA
 PAT
 PBT
 Business Strategy
 Merck and Co
 Gilead Sciences
 Novartis AG
 GlaxoSmithKline, plc
 Hoffmann- La Roche
 Bristol-Myers Squibb
Company Coverage
 Hepatitis B virus
Treatment Market, By
Type (2012-2022), By
Value
 Hepatitis B virus
Treatment Market, By
End User (2012-2022),
By Value

3. (c) AZOTH Analytics
S.No Particulars Page No.
1. Research Methodology 23
2. Executive Summary 24
3. Strategic Recommendation 25
3.1 Asia Pacific Region to witness the fastest growth for Hepatitis B market in the forecast period 26
3.2 Therapeutic segment witnessing fastest growth 27
4. Hepatitis B Treatment Market: Product Outlook 28
5. Global Hepatitis B Treatment Market: Growth and Forecast 33
5.1 Global Hepatitis B Treatment Market, By Value (2012-2016) 34
5.2 Global Hepatitis B Treatment Market, By Value (2017-2022) 37
5.3 Global Hepatitis B Treatment Market - By Type, By Value 38
5.3.1 Global Hepatitis B Treatment Market, By Value, % (2016) 38
5.3.2 Global Hepatitis B Treatment Market, By Value, % (Forecast 2022F) 39
5.4 Global Hepatitis B Treatment Market, By Type, By Value (2012-2022) 40
5.4.1 Therapeutics, By Value (2012-2022) 40
5.4.2 Vaccines, By Value (2012-2022) 40
5.5 Global Hepatitis B Treatment Market, By End-User, By Value (2012-2022) 42
5.5.1 Male, By Value (2012-2022) 42
5.5.2 Female, By Value (2012-2022) 42
Table of Content
3

4. (c) AZOTH Analytics
S.No Particulars Page No.
6. North America Hepatitis B Treatment Market: Growth and Forecast 47
6.1 North America Hepatitis B Treatment Market, By Value (2012-2016) 48
6.2 North America Hepatitis B Treatment Market, By Value (2017-2022) 48
6.3 North America Hepatitis B Treatment Market - By Type, By Value 51
6.3.1 North America Hepatitis B Treatment Market, By Value, % (2016) 51
6.3.2 North America Hepatitis B Treatment Market, By Value, % (Forecast 2022F) 52
6.4 North America Hepatitis B Treatment Market, By Type, By Value (2012-2022) 53
6.4.1 Therapeutics, By Value (2012-2022) 53
6.4.2 Vaccines, By Value (2012-2022) 53
6.5 North America Hepatitis B Treatment Market, By End-User, By Value (2012-2022) 54
6.5.1 Male, By Value (2012-2022) 54
6.5.2 Female, By Value (2012-2022) 54
6.6 North America Hepatitis B Treatment Market: Country Analysis (U.S., Canada) 55
6.6.1 North America Hepatitis B Treatment Market, Country Share, 2016 (% of Total) 55
6.6.2 North America Hepatitis B Treatment Market, Country Share, 2022 (% of Total) 55
Table of Content
4

5. (c) AZOTH Analytics
Table of Content
S. No Particulars Page No.
6.7 U.S. Hepatitis B Treatment Market: Growth and Forecast 57
6.7.1 U.S. Hepatitis B Treatment Market, By Value (2012-2016) 58
6.7.2 U.S. Hepatitis B Treatment Market, By Value (2017-2022) 58
6.8 U.S. Hepatitis B Treatment Market - By Type, By Value 62
6.8.1 Therapeutics, By Value (2012-2022) 62
6.8.2 Vaccines, By Value (2012-2022) 62
6.9 U.S. Hepatitis B Treatment Market - By End-User, By Value 63
6.9.1 Male, By Value (2012-2022) 63
6.9.2 Female, By Value (2012-2022) 63
6.10 Canada Hepatitis B Treatment Market: Growth and Forecast 65
6.10.1 Canada Hepatitis B Treatment Market, By Value (2012-2016) 66
6.10.2 Canada Hepatitis B Treatment Market, By Value (2017-2022) 66
6.11 Canada Hepatitis B Treatment Market - By Type, By Value 69
6.11.1 Therapeutics, By Value (2012-2022) 69
6.11.2 Vaccines, By Value (2012-2022) 69
6.12 Canada Hepatitis B Treatment Market - By End-User, By Value 70
6.12.1 Male, By Value (2012-2022) 70
6.12.2 Female, By Value (2012-2022) 70
5

6. (c) AZOTH Analytics
S.No Particulars Page No.
7. Europe Hepatitis B Treatment Market: Growth and Forecast 71
7.1 Europe Hepatitis B Treatment Market, By Value (2012-2016) 72
7.2 Europe Hepatitis B Treatment Market, By Value (2017-2022) 72
7.3 Europe Hepatitis B Treatment Market - By Type, By Value 75
7.3.1 Europe Hepatitis B Treatment Market, By Value, % (2016) 75
7.3.2 Europe Hepatitis B Treatment Market, By Value, % (Forecast 2022F) 76
7.4 Europe Hepatitis B Treatment Market, By Type, By Value (2012-2022) 77
7.4.1 Therapeutics, By Value (2012-2022) 77
7.4.2 Vaccines, By Value (2012-2022) 77
7.5 Europe Hepatitis B Treatment Market, By End-User, By Value (2012-2022) 78
7.5.1 Male, By Value (2012-2022) 78
7.5.2 Female, By Value (2012-2022) 78
Table of Content
6

7. (c) AZOTH Analytics
Table of Content
S. No Particulars Page No.
7.6 Europe Hepatitis B Treatment Market: Country Analysis (U.K., Germany, France) 79
7.6.1 Europe Hepatitis B Treatment Market, Country Share, 2016 (% of Total) 79
7.6.2 Europe Hepatitis B Treatment Market, Country Share, 2022 (% of Total) 79
7.7 U.K. Hepatitis B Treatment Market: Growth and Forecast 81
7.7.1 U.K. Hepatitis B Treatment Market, By Value (2012-2016) 82
7.7.2 U.K. Hepatitis B Treatment Market, By Value (2017-2022) 82
7.8 U.K. Hepatitis B Treatment Market - By Type, By Value 86
7.8.1 Therapeutics, By Value (2012-2022) 86
7.8.2 Vaccines, By Value (2012-2022) 86
7.9 U.K. Hepatitis B Treatment Market - By End-User, By Value 87
7.9.1 Male, By Value (2012-2022) 87
7.9.2 Female, By Value (2012-2022) 87
7.10 Germany Hepatitis B Treatment Market: Growth and Forecast 88
7.10.1 Germany Hepatitis B Treatment Market, By Value (2012-2016) 89
7.10.2 Germany Hepatitis B Treatment Market, By Value (2017-2022) 89
7

8. (c) AZOTH Analytics
Table of Content
S. No Particulars Page No.
7.11 Germany Hepatitis B Treatment Market - By Type, By Value 92
7.11.1 Therapeutics, By Value (2012-2022) 92
7.11.2 Vaccines, By Value (2012-2022) 92
7.12 Germany Hepatitis B Treatment Market - By End-User, By Value 93
7.12.1 Male, By Value (2012-2022) 93
7.12.2 Female, By Value (2012-2022) 93
7.13 France Hepatitis B Treatment Market: Growth and Forecast 94
7.13.1 France Hepatitis B Treatment Market, By Value (2012-2016) 95
7.13.2 France Hepatitis B Treatment Market, By Value (2017-2022) 95
7.14 France Hepatitis B Treatment Market - By Type, By Value 98
7.14.1 Therapeutics, By Value (2012-2022) 98
7.14.2 Vaccines, By Value (2012-2022) 98
7.15 France Hepatitis B Treatment Market - By End-User, By Value 99
7.15.1 Male, By Value (2012-2022) 99
7.15.2 Female, By Value (2012-2022) 99
8

9. (c) AZOTH Analytics
S.No Particulars Page No.
8. Asia-Pacific Hepatitis B Treatment Market: Growth and Forecast 100
8.1 Asia-Pacific Hepatitis B Treatment Market, By Value (2012-2016) 101
8.2 Asia-Pacific Hepatitis B Treatment Market, By Value (2017-2022) 101
8.3 Asia-Pacific Hepatitis B Treatment Market - By Type, By Value 103
8.3.1 Asia-Pacific Hepatitis B Treatment Market, By Value, % (2016) 103
8.3.2 Asia-Pacific Hepatitis B Treatment Market, By Value, % (Forecast 2022F) 104
8.4 Asia-Pacific Hepatitis B Treatment Market, By Type, By Value (2012-2022) 105
8.4.1 Therapeutics, By Value (2012-2022) 105
8.4.2 Vaccines, By Value (2012-2022) 105
8.5 Asia-Pacific Hepatitis B Treatment Market, By End-User, By Value (2012-2022) 106
8.5.1 Male, By Value (2012-2022) 106
8.5.2 Female, By Value (2012-2022) 106
8.6 Asia-Pacific Hepatitis B Treatment Market: Country Analysis (Japan, China, India) 107
Table of Content
9

10. (c) AZOTH Analytics
Table of Content
S. No Particulars Page No.
8.6.1 Asia-Pacific Hepatitis B Treatment Market, Country Share, 2016 (% of Total) 107
8.6.2 Asia-Pacific Hepatitis B Treatment Market, Country Share, 2022 (% of Total) 107
8.7 Japan Hepatitis B Treatment Market: Growth and Forecast 109
8.7.1 Japan Hepatitis B Treatment Market, By Value (2012-2016) 110
8.7.2 Japan Hepatitis B Treatment Market, By Value (2017-2022) 110
8.8 Japan Hepatitis B Treatment Market - By Type, By Value 113
8.8.1 Therapeutics, By Value (2012-2022) 113
8.8.2 Vaccines, By Value (2012-2022) 113
8.9 Japan Hepatitis B Treatment Market - By End-User, By Value 114
8.9.1 Male, By Value (2012-2022) 114
8.9.2 Female, By Value (2012-2022) 114
8.10 China Hepatitis B Treatment Market: Growth and Forecast 115
8.10.1 China Hepatitis B Treatment Market, By Value (2012-2016) 116
8.10.2 China Hepatitis B Treatment Market, By Value (2017-2022) 116
10

11. (c) AZOTH Analytics
Table of Content
S. No Particulars Page No.
8.11 China Hepatitis B Treatment Market - By Type, By Value 119
8.11.1 Therapeutics, By Value (2012-2022) 119
8.11.2 Vaccines, By Value (2012-2022) 119
8.12 China Hepatitis B Treatment Market - By End-User, By Value 120
8.12.1 Male, By Value (2012-2022) 120
8.12.2 Female, By Value (2012-2022) 120
8.13 India Hepatitis B Treatment Market: Growth and Forecast 122
8.13.1 India Hepatitis B Treatment Market, By Value (2012-2016) 123
8.13.2 India Hepatitis B Treatment Market, By Value (2017-2022) 123
8.14 India Hepatitis B Treatment Market - By Type, By Value 126
8.14.1 Therapeutics, By Value (2012-2022) 126
8.14.2 Vaccines, By Value (2012-2022) 126
8.15 India Hepatitis B Treatment Market - By End-User, By Value 127
8.15.1 Male, By Value (2012-2022) 127
8.15.2 Female, By Value (2012-2022) 127
11

12. (c) AZOTH Analytics
Table of Content
S. No Particulars Page No.
9. ROW Hepatitis B Treatment Market: Growth and Forecast 128
9.1 ROW Hepatitis B Treatment Market, By Value (2012-2016) 129
9.2 ROW Hepatitis B Treatment Market, By Value (2017-2022) 129
10. Market Dynamics 132
10.1
Increasing prevalence of Liver diseases due to Hepatitis B
134
10.2
Increasing awareness about the Hepatitis B & HBV
135
10.3 Rising healthcare expenditure worldwide 136
11. Market Restraints 137
12. SWOT Analysis – Hepatitis B Treatment Market 141
13. Porter’s Five Forces Analysis 143
14. Policy and Regulations 145
15. Global Hepatitis B Drugs Pipeline 153
16. Global Hepatitis B Treatment Market - Competitive Landscape 159
12

13. (c) AZOTH Analytics
Table of Content
S. No Particulars Page No.
17. Company Profile 161
17.1
Merck and Co
162
17.2
Gilead Sciences
165
17.3
Novartis AG
167
17.4
GlaxoSmithKline, plc
169
17.5
F.Hoffmann- La Roche
172
17.6
Bristol-Myers Squibb
175
17.7
AbbVie Inc
179
18. About US 181
13

14. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 1: Global Hepatitis B Treatment Market Size, By Value, 2012-2016 (USD Million) 34
Figure 2: Number of patients with Hepatitis B Virus (HBsAg) infection by WHO region, 2015 (In Million) 35
Figure 3: Global Healthcare Expenditure, 2012-2016 (In Trillion) 36
Figure 4: Global Hepatitis B Treatment Market Size, By Value, 2017-2022 (USD Million) 37
Figure 5: Global Hepatitis B Treatment Market Size, By Type, 2016 (%) 38
Figure 6: Global Hepatitis B Treatment Market Size, By Type, 2022 (%) 39
Figure 7: Global Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million) 40
Figure 8: Global Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million) 42
Figure 9: Global Sales of HBV approved Drugs, By Value, 2014-2016 (USD Million) 43
Figure 10: Global Sales of Viread, By Value, 2015-2016 (USD Million) 43
Figure 11: Global Hepatitis B Treatment Market Size, By Region, 2016 (%) 45
Figure 12: Global Hepatitis B Treatment Market Size, By Region, 2022 (%) 46
Figure 13: North America Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million) 48
Figure 14: North America GDP, 2012-2015 (USD Trillion) 49
Figure 15: North America GDP, By Select Country, 2016 (USD Trillion) 49
Figure 16: Population aged 65 & above, 2012-2016 (% of total) 50
Figure 17: North America Hepatitis B Treatment Market Size, By Type, 2016 (%) 51
Figure 18: North America Hepatitis B Treatment Market Size, By Type, 2022 (%) 52
Figure 19: North America Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million) 53
14

15. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 20: North America Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million) 54
Figure 21: North America Hepatitis B Treatment Market, Country Share, 2016 (% of Total) 55
Figure 22: North America Hepatitis B Treatment Market, Country Share, 2022 (% of Total) 55
Figure 23: U.S. Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million) 58
Figure 24: U.S. Per Capita Healthcare Expenditure, 2012-2016 (In USD) 60
Figure 25: Reported acute (new) cases of Hepatitis B Virus in U.S., (2012-2015) 60
Figure 26: Incidences rate of acute Hepatitis B in U.S., By sex (2012-2015) 60
Figure 27: Incidence of acute Hepatitis B in U.S., By age group, (2012-2015) 61
Figure 28: U.S. Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million) 62
Figure 29: U.S. Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million) 63
Figure 30: Market Share of HBV approved Drugs in U.S., 2016 (% Share) 64
Figure 31: Canada Hepatitis B Treatment Market Size, By Value, 2012-2022 (USD Million) 66
Figure 32: Canada Per Capita Healthcare Expenditure, 2012-2016 (In USD) 67
Figure 33: Canada Life Expectancy at birth rate (Years), 2012-2015 67
Figure 34: Prevalence of Hepatitis B in Canada, (Patients per 100,000 (2012-2016) 67
Figure 35: Number of Hepatitis B Patients, Canada, (2013-2016) 67
Figure 36: Prevalence of Hepatitis B among Male population, Canada, (Patients per 100,000) (2012-2016) 68
Figure 37: Prevalence of Hepatitis B among Female population, Canada, (Patients per 100,000) (2012-2016) 68
Figure 38: Canada Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million) 69
Figure 39: Canada Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million) 70
15

16. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 40: Canada Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million) 72
Figure 41: European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD) 73
Figure 42: European Union Life Expectancy at birth rate (Years), 2012-2015 73
Figure 43: Reported Hepatitis B Cases, Number & Rate per 100,000 populations, EU/EEA, 2012-2015 73
Figure 44: Acute & Chronic Hepatitis B cases, rate per 100,000 populations, By Age Group, 2015 74
Figure 45: Acute & Chronic Hepatitis B cases, rate per 100,000 populations, By Age Group, 2015 74
Figure 46: Europe Hepatitis B Treatment Market Size, By Type, 2016 (%) 75
Figure 47: Europe Hepatitis B Treatment Market Size, By Type, 2022 (%) 76
Figure 48: Europe Hepatitis B Treatment Market- By Type, By Value 2012-2022 (USD Million) 77
Figure 49: Europe Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million) 78
Figure 50: Europe Hepatitis B Treatment, Country Share, 2016 (% of Total) 79
Figure 51: Europe Hepatitis B Treatment, Country Share, 2022 (% of Total) 79
Figure 52: U.K. Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million) 82
Figure 53: U.K. Population 65 Years & Above (% of Total), 2012-2016 84
Figure 54: U.K. Life Expectancy at birth rate (Years), 2012-2015 84
Figure 55: U.K. Women Population, 2012-2016 84
Figure 56: U.K., Per Capita Healthcare Expenditure, 2012-2014 (In USD) 84
Figure 57: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016) 85
Figure 58: Number of Hepatitis B Patients, (2013-2016) 85
Figure 59: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016) 85
Figure 60: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016) 85
16

17. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 61: U.K. Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million) 86
Figure 62: U.K. Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million) 87
Figure 63: Germany Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million) 89
Figure 64: Germany Population 65 Years & Above (% of Total), 2012-2016 90
Figure 65: Germany Life Expectancy at birth rate (Years), 2012-2015 90
Figure 66: Germany Women Population, 2012-2016 90
Figure 67: Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD) 90
Figure 68: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016) 91
Figure 69: Number of Hepatitis B Patients, (2013-2016) 91
Figure 70: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016) 91
Figure 71: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016) 91
Figure 72: Germany Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million) 92
Figure 73: Germany Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million) 93
Figure 74: France Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million) 95
Figure 75: France Population 65 Years & Above (% of Total), 2012-2016 96
Figure 76: France Life Expectancy at birth rate (Years), 2012-2015 96
Figure 77: France Women Population, 2012-2016 96
Figure 78: France Per Capita Healthcare Expenditure, 2012-2014 (In USD) 96
Figure 79: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016) 97
Figure 80: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016) 97
17

18. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 81: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016) 97
Figure 82: France Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million) 98
Figure 83: France Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million) 99
Figure 84: Asia-Pacific Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million) 101
Figure 85: Mortality due to Viral Hepatitis in South-East Asia region, 2015 102
Figure 86: Asia-Pacific Hepatitis B Treatment Size, By Type, 2016 (%) 103
Figure 87: Asia-Pacific Hepatitis B Drug Market Size, By Type, 2022 (%) 104
Figure 88: Asia-pacific Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million) 105
Figure 89: Asia-Pacific Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million) 106
Figure 90: Asia-Pacific Hepatitis B Treatment, Country Share, 2016 (% of Total) 107
Figure 91: Asia-Pacific Hepatitis B Treatment, Country Share, 2022 (% of Total) 107
Figure 92: Japan Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million) 110
Figure 93: Japan Population 65 Years & Above (% of Total), 2012-2016 111
Figure 94: Japan Life Expectancy at birth rate (Years), 2012-2015 111
Figure 95: Japan, Per Capita Healthcare Expenditure, 2012-2014 (In USD) 111
Figure 96: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016) 112
Figure 97: Number of Hepatitis B Patients, 2013-2016) 112
Figure 98: Prevalence of Hepatitis B among Male population (Patients per 100,000 (2012-2016) 112
Figure 99: Prevalence of Hepatitis B among Female population (Patients per 100,000 (2012-2016) 112
Figure 100: Japan Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million) 113
18

19. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 101: Japan Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million) 114
Figure 102: China Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million) 116
Figure 103: China Population 65 Years & Above (% of Total), 2012-2016 118
Figure 104: China Life Expectancy at birth rate (Years), 2012-2015 118
Figure 105: China Women Population, 2012-2016 118
Figure 106: China Per Capita Healthcare Expenditure, 2012-2014 (In USD) 118
Figure 107: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016) 119
Figure 108: Number of Hepatitis B Patients, 2013-2016) 119
Figure 109: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016) 119
Figure 110: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016) 119
Figure 111: China Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million) 120
Figure 112: China Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million) 121
Figure 113: India Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million) 123
Figure 114: India Population 65 Years & Above (% of Total), 2012-2016 124
Figure 115: India Life Expectancy at birth rate (Years), 2012-2015 124
Figure 116: India Women Population, 2012-2016 124
Figure 117: India Per Capita Healthcare Expenditure, 2012-2014 (In USD) 124
Figure 118: Prevalence of Hepatitis B (Patients per 100,000 (2012-2016) 125
Figure 119: Number of Hepatitis B Patients, 2013-2016) 125
Figure 120: Prevalence of Hepatitis B among Male population (Patients per 100,000) (2012-2016) 125
19

20. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 121: Prevalence of Hepatitis B among Female population (Patients per 100,000) (2012-2016) 125
Figure 122: India Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million) 126
Figure 123: India Hepatitis B Treatment- By End-User, By Value 2012-2022 (USD Million) 127
Figure 124: ROW Hepatitis B Treatment Size, By Value, 2012-2022 (USD Million) 129
Figure 125: Prevalence of Hepatitis B in Brazil (Patients per 100,000 (2012-2016) 130
Figure 126: Number of Hepatitis B Patients in Brazil, (2013-2016) 130
Figure 127: Prevalence of Hepatitis B among Male population, in Brazil (Patients per 100,000) (2012-2016) 130
Figure 128: Prevalence of Hepatitis B among Female population in Brazil (Patients per 100,000) (2012-2016) 130
Figure 129: Prevalence of Hepatitis B in South Africa (Patients per 100,000 (2012-2016) 131
Figure 130: Number of Hepatitis B Patients in South Africa, (2013-2016) 131
Figure 131: Prevalence of Hepatitis B among Male population, in South Africa (Patients per 100,000) (2012-2016) 131
Figure 132: Prevalence of Hepatitis B among Female population (Patients per 100,000), in South Africa (2012-2016) 131
Figure 133: Global Healthcare Expenditure, 2012-2016 (In Trillion) 136
Figure 134: Global Sales of HBV approved Drugs, By Value, 2014-2016 (USD Million) 159
Figure 135: Global Sales of Viread, By, Region, By Value, 2015-2016 (USD Million) 159
Figure 136: Merck & Co., Net Sales, 2012-2016 (In million USD) 163
Figure 137: Merck & Co, Net Sales of Gardasil/Gardasil 9, 2012-2016 (In million USD) 163
Figure 138: Merck & Co., Net Sales, By Geographic Location, % Share 2016 163
Figure 139: Merck & Co., Net Revenue, By Business Segment, % Share 2016 163
Figure 140: Gilead Sciences Annual Revenue, 2014-2016 (USD Million) 166
20

21. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 141: Gilead Sciences HBV Product Sales, 2014-2016 (USD Million) 166
Figure 142: Gilead Sciences Revenue by Geographical, 2016 (%) 166
Figure 143: Gilead Sciences Product Sales, 2016 (%) 166
Figure 144: Novartis Annual Revenue, 2014-2016 (USD Million) 168
Figure 145: Innovative Medicine net Sales, By Business Unit 2016 (%) 168
Figure 146: Novartis Sales, By Region, 2016 (%) 168
Figure 147: Novartis Sales, By Segment 2016 (%) 168
Figure 148: GlaxoSmithKline Annual Revenue, 2014-2016 (USD Million) 170
Figure 149: Sales from Hepatitis Vaccination, GlaxoSmithKline, 2015 - 2016 (USD Million) 170
Figure 150: Glaxosmithkline Sales, By Region, 2016 (%) 170
Figure 151: Glaxosmithkline, Sales, By Segment 2016 (%) 170
Figure 152: F. Hoffmann-La Roche Ltd Annual Revenue, 2014-2016 (USD Million) 173
Figure 153: F. Hoffmann-La Roche Ltd Segmental Break Up, By Revenue, By Business Division, 2016 (%) 173
Figure 154: F. Hoffmann-La Roche Ltd Geographical Break Up, By Revenue, 2016 (%) 173
Figure 155: Bristol-Myers Squibb Company Annual Revenue, 2014-2016 (USD Million) 176
Figure 156: Bristol-Myers Squibb Company Segmental Break Up, By Revenue, By Products, 2016 (%) 176
Figure 157: Bristol-Myers Squibb Company Geographical Break Up, By Revenue, 2016 (%) 176
Figure 158: Baraclude (entecavir), Annual Revenue, 2014-2016 (USD Million) 177
21

22. (c) AZOTH Analytics
List of Figures
Figure No. Figure Title Page No.
Figure 159: Baraclude (entecavir), Segmental Break Up, By geographical segment, 2016 (%) 177
Figure 160: AbbVie Revenue, Segmental Break Up, 2016 180
Figure 161: AbbVie Revenue, Geographical Break Up, 2016 180
Table A: Causes of Hepatitis B 29
Table B: HBV Approved Therapies 31
Table C: Globally Approved HBV Monovalent Vaccines 32
Table D: Compounds in development for chronic Hepatitis B 154
22

23. (c) AZOTH Analytics
Research Methodology
For our study on Global Hepatitis B Treatment Market, we have conducted comprehensive secondary research
followed by an extensive primary research. In the process of secondary research, we have scrutinized industry
documents, accessed from open sources, premium paid databases (Bloomberg, Thomson Reuters, Factiva) and
our internal knowledge base. In the process of primary research, we have interviewed various industry experts
across the value chain of Hepatitis B Treatment Market.
Market size of the actual period (2012-2016) has been evaluated on the basis of growth trends of the industry
in the last five years, and confirming the findings through primary research. Annual reports of the companies
are scanned to further validate the market size and to estimate the size of various other end-user sectors.
Market sizing and growth in the forecast period (2017-2022) is estimated through product mapping,
application in end-user industries, growth of allied sectors and historical growth pattern of the industry. All the
relevant data points/ statistics in the forecast period are validated through relevant and reliable primary
sources.
Report Focus: Hepatitis B Treatment Market
- By Type – Therapeutics, Vaccine
- By Region- North America, Europe, APAC and ROW
- By Country - United States, Canada, United Kingdom, Germany, France, China, India, Japan
Company Analysis
Companies Contacted: GlaxoSmithKline Pharmaceuticals Ltd, Mylan Laboratories India Pvt Ltd
23

24. (c) AZOTH Analytics
Global Hepatitis B Treatment Market – Sizing and Growth
Source: Azoth Analytics Estimates
Figure : Global Hepatitis B Treatment Market Size, By Value, 2012-2016 (USD Million)
High prevalence of Hepatitis B, improving access to diagnosis coupled with growing efforts to reduce
large disease burden due to HBV infection is propelling the global market growth rate
Xxxxx
Xxxxx
Xxxxx
Xxxxx
xxxxx
2012 2013 2014 2015 2016
CAGR 2012-2016
Hepatitis B: xxxx%;
24

25. (c) AZOTH Analytics
Global Hepatitis B Treatment Market - Regional Analysis
Figure : Global Hepatitis B Treatment Market Size, By
Region, 2022 (%)
In the forecast period, North America is anticipated to hold it’s leading position in the market. However,
Asia Pacific region is expected to grow at the highest pace.
Source: Azoth Analytics Estimates
North America
Europe
Asia-Pacific
ROW
Xxxxx
xxxxx
Xxxxx
xxxxx
Xxxxx
xxxxx
Key Drivers
25

26. (c) AZOTH Analytics
North America Hepatitis B Treatment Market- By Country Share
Figure : North America Hepatitis B Treatment Market,
Country Share, 2016 (% of Total)
United States
Canada
Source: Azoth Analytics Estimates
Figure : North America Hepatitis B Treatment Market,
Country Share, 2022 (% of Total)
United States
Canada
Source: Azoth Analytics Estimates
26

27. (c) AZOTH Analytics
Europe Hepatitis B Treatment Market- By End-User, By Value
Figure : Europe Hepatitis B Treatment Market- By End-User, By Value 2012-2022 (USD Million)
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR 2012-2016
Male: xx%; Female: xx%
CAGR 2017-2022
Male: xx%; Female: xx%
Xxxxx
Xxxxx
Xxxxx
Xxxxx
Xxxxxx
xxxxxx
Source: Azoth Analytics Estimates
27

28. (c) AZOTH Analytics
China Hepatitis B Treatment Market - By Type, By Value
Figure : China Hepatitis B Treatment- By Type, By Value 2012-2022 (USD Million)
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR 2012-2016
Therapeutics: xx%; Vaccines: xx%
CAGR 2017-2022
Therapeutics: xx%; Vaccines: xx%
Xxxxx
Xxxxx
Xxxxx
Xxxxx
Xxxxx
xxxxx
Source: Azoth Analytics Estimates
28

29. (c) AZOTH Analytics
About Azoth Analytics Pvt Ltd.
Azoth Analytics is a business research and analytics firm that creates in-depth research reports and provides customized research solutions and consultancy
services. Verticals in which Azoth Analytics specializes include healthcare and pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food &
beverages and technology. Azoth creates comprehensive and in-depth research reports by recording, interpreting and analyzing information. Strategic
market sizing and data dredging techniques include secondary research, and primary research (interviews with management personnel and industry experts).
Related Reports:
Global Oxygen Therapy Equipment Market - Analysis By Product, Portability, Application, Region, Country: Opportunities and Forecast
(2017- 2022) -- By Product (Oxygen Concentrators, Liquid Oxygen Devices and Oxygen Cylinders), By Portability (Stationary, Portable
Devices), By Application (COPD, Asthma, Cystic Fibrosis, Respiratory Distress Syndrome)
Global Industrial X-Ray Inspection System Market - By Imaging Technique, By Digital Imaging Type, By Digital Radiography Type, By End
User, By Region, By Country (2017-2022) -- By Imaging Technique (Film Based, Digital), By Digital Imaging Type (Digital Radiography,
Computed Tomography), By Digital Radiography Type (Direct Digital, Computed Radiography)
Disclaimer: Azoth Analytics report information is based mainly on interviews and therefore, is subject to fluctuation. Azoth Analytics therefore, takes no responsibility for
any incorrect information supplied to us by industry experts, manufacturers or users. Azoth does not warranty the completeness of the information and data. Also, analysis
provided in the report are meant for customers’ internal use only and not for general publication or disclosure to third parties.
29